Denali Therapeutics
DNLI
58 hedge funds and large institutions have $1.2B invested in Denali Therapeutics in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 15 closing their positions.
328% more capital inflows, than outflows
Capital inflows: $82.5M | Capital outflows: $19.3M
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
29% more funds holding
Funds holding: 45 → 58 (+13)
0.12% more ownership
Funds ownership: 64.56% → 64.69% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$21.7M |
| 2 |
BAMCO Inc
New York
|
+$8.71M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.64M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$5.85M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$5.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$7.9M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.85M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$1.48M |
| 4 |
Millennium Management
New York
|
-$1.48M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.07M |
DNLI Hedge Fund Activity: Q1 2018 in Review
58 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q1 2018, worth a combined $1.2B — up 32% from $909M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new DNLI positions and 15 closed out — a net gain of 13 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $21.7M. The largest seller was Norges Bank, cutting an estimated $7.9M.
- 58 institutional investors held Denali Therapeutics (DNLI) as of Q1 2018, up from 45 in Q4 2017.
- Funds reported $1.2B of Denali Therapeutics stock for Q1 2018, up 32% quarter-over-quarter.
- 28 funds opened new Denali Therapeutics positions in Q1 2018 and 15 closed out, a net change of +13 holders.
- The largest Denali Therapeutics buyer in Q1 2018 was BlackRock, an estimated $21.7M added.
- The largest Denali Therapeutics seller in Q1 2018 was Norges Bank, an estimated $7.9M sold.
Based on aggregated 13F filings for Q1 2018.